Neurology
MS Regulators Are No Longer Reading the Same Risk
Europe has authorised tolebrutinib for non-relapsing secondary progressive MS. FDA rejected the same application over benefit-risk concerns. The regulatory split is now part of the treatment story.
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
Europe’s Mental Health Projects Move From Crisis Talk to Delivery Tools
Europe’s Epilepsy Rules Start Catching Up With Precision Treatment
SMA Screening Shows Precision Neurology Starts Before Symptoms
Post-Stroke Cognitive Screening Needs Local Tools
Europe’s Stroke Plan Turns Speed Into a Policy Test
Parkinson’s Research Moves From Tracking Progression to Defining Biology
MS Monitoring Starts Moving Beyond the MRI Bottleneck
Latin America Challenges the Dementia Biomarker Evidence Gap
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.